Double Bond Pharmaceutical reported lower revenues and continued losses in H1 2024, but advanced SI-053 development and secured new financing and partnerships, including a key deal with Vivo Biopharma.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.